GlassScriptPhysician profile
Angelos Halaris
NPI 1891762621
$93,941.57
in general payments reported to CMS, 2019-2025
26 companies · $698 in 2025
The $698 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $17K · 2021: $4,804 · 2022: $29K · 2023: $780 · 2024: $1,059 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.43 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $90,276.55 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,210.52 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $488.25 | 2019-2025 | Ingrezza |
| Biogen, INC. | $484.39 | 2022-2023 | |
| Alkermes, INC. | $245.42 | 2022-2025 | Lybalvi, Aristada |
| Janssen Scientific Affairs, LLC | $229.39 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $209.65 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $122.25 | 2021-2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $115.06 | 2024-2025 | Auvelity |
| Abbvie INC. | $90.66 | 2025 | |
| Corium, LLC | $81.85 | 2023-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $59.61 | 2021-2022 | |
| Sage Therapeutics, LLC | $47.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.77 | 2021-2022 | |
| Brainsway USA INC | $41.32 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.79 | 2022 | |
| Tms Neurohealth Centers INC. | $34.39 | 2025 | Tms Neurohealth Centers INC. |
| Vanda Pharmaceuticals INC. | $33.50 | 2024 | Fanapt |
| Tris Pharma INC | $22.44 | 2025 | Dyanavel Xr |
| Bausch Health US, LLC | $15.71 | 2024 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $14.81 | 2022 | |
| Almatica Pharma LLC | $14.23 | 2021 | |
| Noven Therapeutics, LLC | $13.25 | 2024 | Xelstrym, Secuado |
| Allergan, INC. | $11.67 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelos Halaris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.